The innate branch of the immune system is the first response to threats in the body, including pathogens and cancer. Subsequently, the rest of the immune system is activated to specifically combat these threats. Targeting innate immune pathways is a promising strategy towards novel cancer therapeutics. STING (STimulator of INterferon Genes) is one such pathway whose modulation has clear therapeutic benefits. However, we do not fully understand the metabolism and regulation of the STING pathway’s activating small molecule ligand. My project combines chemical biology, cell biology, and immunology to characterize the metabolism of this small molecule. This mechanistic picture will enable precise enhancement of STING activation to treat cancer.